GW&K Investment Management LLC Purchases 134,063 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

GW&K Investment Management LLC lifted its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 19.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 817,526 shares of the biopharmaceutical company's stock after purchasing an additional 134,063 shares during the quarter. GW&K Investment Management LLC owned about 1.41% of Agios Pharmaceuticals worth $23,954,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in AGIO. GAMMA Investing LLC grew its holdings in Agios Pharmaceuticals by 9,296.6% in the 1st quarter. GAMMA Investing LLC now owns 8,175 shares of the biopharmaceutical company's stock worth $240,000 after buying an additional 8,088 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in shares of Agios Pharmaceuticals by 3.3% during the 4th quarter. Envestnet Asset Management Inc. now owns 24,805 shares of the biopharmaceutical company's stock valued at $815,000 after acquiring an additional 795 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Agios Pharmaceuticals by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock valued at $185,045,000 after purchasing an additional 85,339 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Agios Pharmaceuticals by 0.9% in the fourth quarter. Northern Trust Corp now owns 595,480 shares of the biopharmaceutical company's stock valued at $19,567,000 after purchasing an additional 5,372 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Agios Pharmaceuticals in the fourth quarter valued at $4,768,000.

Agios Pharmaceuticals Stock Down 0.7%

AGIO traded down $0.28 during trading on Friday, hitting $39.37. The company had a trading volume of 131,862 shares, compared to its average volume of 665,491. The firm's 50-day moving average price is $34.77 and its 200 day moving average price is $32.46. Agios Pharmaceuticals, Inc. has a one year low of $23.42 and a one year high of $62.58. The company has a market capitalization of $2.28 billion, a PE ratio of 3.50 and a beta of 0.73.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. The company had revenue of $8.73 million for the quarter, compared to analysts' expectations of $9.86 million. Agios Pharmaceuticals had a net margin of 1,798.26% and a negative return on equity of 2.75%. Sell-side analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AGIO has been the subject of several recent research reports. Wall Street Zen lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, May 19th. Bank of America lowered their target price on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a research report on Tuesday. Finally, Scotiabank lowered their price target on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research report on Friday, May 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Agios Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $57.33.

Insiders Place Their Bets

In related news, CFO Cecilia Jones sold 1,780 shares of the company's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total value of $59,701.20. Following the transaction, the chief financial officer owned 30,049 shares in the company, valued at approximately $1,007,843.46. This represents a 5.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Brian Goff sold 18,700 shares of the stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total transaction of $627,198.00. Following the transaction, the chief executive officer owned 105,401 shares in the company, valued at approximately $3,535,149.54. The trade was a 15.07% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 46,363 shares of company stock worth $1,619,654 in the last 90 days. Corporate insiders own 4.30% of the company's stock.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.